SILENCE THERAP. SP.ADR/1 - Asset Resilience Ratio
SILENCE THERAP. SP.ADR/1 (XRP2) has an Asset Resilience Ratio of 56.17% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of SILENCE THERAP. SP.ADR/1 for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how SILENCE THERAP. SP.ADR/1's Asset Resilience Ratio has changed over time. See what is SILENCE THERAP. SP.ADR/1's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down SILENCE THERAP. SP.ADR/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SILENCE THERAP. SP.ADR/1 market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €73.84 Million | 56.17% |
| Total Liquid Assets | €73.84 Million | 56.17% |
Asset Resilience Insights
- Very High Liquidity: SILENCE THERAP. SP.ADR/1 maintains exceptional liquid asset reserves at 56.17% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
SILENCE THERAP. SP.ADR/1 Industry Peers by Asset Resilience Ratio
Compare SILENCE THERAP. SP.ADR/1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.70% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.64% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 2.21% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 82.25% |
Annual Asset Resilience Ratio for SILENCE THERAP. SP.ADR/1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for SILENCE THERAP. SP.ADR/1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 56.17% | €73.84 Million ≈ $86.32 Million |
€131.44 Million ≈ $153.67 Million |
+43.34pp |
| 2024-12-31 | 12.83% | €26.00 Million ≈ $30.40 Million |
€202.63 Million ≈ $236.90 Million |
-- |
| 2023-12-31 | 0.00% | €0.00 ≈ $0.00 |
€119.45 Million ≈ $139.65 Million |
-- |
| 2022-12-31 | 15.19% | €19.76 Million ≈ $23.10 Million |
€130.10 Million ≈ $152.10 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€129.83 Million ≈ $151.78 Million |
-- |
About SILENCE THERAP. SP.ADR/1
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated … Read more